| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NCEH1 |
| Uniprot No | Q6PIU2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-408aa |
| 氨基酸序列 | SVSDPWKLMLLDATFRGAQQVSNLIHYLGLSHHLLALNFIIVSFGKKSAWSSAQVKVTDTDFDGVEVRVFEGPPKPEEPLKRSVVYIHGGGWALASAKIRYYDELCTAMAEELNAVIVSIEYRLVPKVYFPEQIHDVVRATKYFLKPEVLQKYMVDPGRICISGDSAGGNLAAALGQQFTQDASLKNKLKLQALIYPVLQALDFNTPSYQQNVNTPILPRYVMVKYWVDYFKGNYDFVQAMIVNNHTSLDVEEAAAVRARLNWTSLLPASFTKNYKPVVQTTGNARIVQELPQLLDARSAPLIADQAVLQLLPKTYILTCEHDVLRDDGIMYAKRLESAGVEVTLDHFEDGFHGCMIFTSWPTNFSVGIRTRNSYIKWLDQNL |
| 预测分子量 | 50.7KDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NCEH1重组蛋白的3篇代表性文献(内容为示例性概括，具体文献需根据实际研究补充)：
1. **文献名称**：*Structural and functional characterization of human NCEH1 reveals a regulatory role of its C-terminal domain*
**作者**：Okazaki H, et al.
**摘要**：通过重组表达人源NCEH1蛋白，解析其晶体结构，发现其C端结构域对酶活性的调控作用，并验证了其在胆固醇酯水解中的关键催化位点。
2. **文献名称**：*NCEH1 deficiency promotes intracellular lipid accumulation and exacerbates Alzheimer's disease pathology in a mouse model*
**作者**：Sakai K, et al.
**摘要**：研究利用重组NCEH1蛋白进行体外酶活补偿实验，证明NCEH1通过水解神经元中的胆固醇酯减少β-淀粉样蛋白沉积，提示其与阿尔茨海默病的潜在关联。
3. **文献名称**：*Optimization of recombinant NCEH1 expression in E. coli for high-throughput drug screening*
**作者**：Chen L, et al.
**摘要**：报道了一种在大肠杆菌中高效表达可溶性NCEH1重组蛋白的方法，并建立基于该蛋白的抑制剂筛选平台，为代谢性疾病药物开发提供工具。
4. **文献名称**：*NCEH1 regulates lipid metabolism through PPARα signaling pathway*
**作者**：Wang Y, et al.
**摘要**：通过重组蛋白功能实验发现，NCEH1水解产生的胆固醇产物可激活PPARα通路，进而调控肝脏脂质代谢，为肥胖治疗提供新靶点。
(注：以上文献为示例，实际研究中需根据具体课题通过PubMed或Google Scholar检索真实文献。)
Neutral cholesterol ester hydrolase 1 (NCEH1), also known as carboxylesterase 1 or cholesterol esterase, is a key enzyme involved in lipid metabolism. It hydrolyzes cholesterol esters into free cholesterol and fatty acids, regulating intracellular cholesterol homeostasis. NCEH1 is primarily expressed in macrophages, liver cells, and steroidogenic tissues, where it plays a critical role in maintaining lipid balance, modulating lipoprotein metabolism, and influencing atherosclerosis progression. Dysregulation of NCEH1 activity has been linked to metabolic disorders, including obesity, fatty liver disease, and cardiovascular pathologies.
Recombinant NCEH1 protein is engineered using molecular cloning techniques, typically expressed in prokaryotic (e.g., E. coli) or eukaryotic systems (e.g., mammalian or insect cells) to ensure proper folding and post-translational modifications. The purified protein retains enzymatic activity, enabling researchers to study its biochemical properties, substrate specificity, and regulatory mechanisms in vitro. Its recombinant form is widely used to investigate lipid droplet dynamics, macrophage foam cell formation, and reverse cholesterol transport pathways.
In drug discovery, recombinant NCEH1 serves as a tool for screening small-molecule modulators targeting atherosclerosis or metabolic syndromes. Structural studies using recombinant protein have revealed its α/β-hydrolase fold and catalytic triad, providing insights for rational drug design. Current research also explores its potential role in neuroprotection and cancer biology, as cholesterol metabolism intersects with multiple cellular processes. The availability of high-purity recombinant NCEH1 accelerates both basic research and therapeutic development in lipid-related diseases.
×
